The entry of HIV-1 into host cells is mediated by precise interactions between viral envelope glycoproteins and cellular receptors. Fusion inhibitors, which disrupt these interactions—particularly by ...

The T-20 vs. Optimized Regimen Only Study 1 (TORO 1) was a randomized, open-label, phase 3 study of enfuvirtide (T-20), a human immunodeficiency virus type 1 (HIV-1) fusion inhibitor. Patients from 48 ...

The oral respiratory syncytial virus (RSV) fusion protein inhibitor AK0529 was found to be well tolerated and reduced viral load in infants. Both viral load and Wang Respiratory Scores improved after ...

Enfuvirtide used as a single agent was originally studied in 17 HIV-infected patients. [8] Seven of these individuals had not previously been exposed to antiretrovirals, and 10 had been previously ...